

Radiotherapy combination opportunities leveraging im practice

Ca-A Cancer Journal for Clinicians

67, 65-85

DOI: [10.3322/caac.21358](https://doi.org/10.3322/caac.21358)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Stereotactic body radiotherapy in the era of radiotherapy with immunotherapy. <i>Journal of Thoracic Disease</i> , 2016, 8, 2968-2970.	0.6	3
2	New initiatives in the treatment of breast cancer. <i>Medical Journal of Australia</i> , 2016, 205, 449-450.	0.8	4
3	The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. <i>Clinical Epigenetics</i> , 2017, 9, 4.	1.8	33
4	Precision radiation oncology: Achievements and challenges. <i>Precision Radiation Oncology</i> , 2017, 1, 4-6.	0.4	2
5	The Future of Radioligand Therapy: $\hat{1}$, $\hat{2}$, or Both?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1017-1018.	2.8	53
6	Recent developments in radiotherapy for small-cell lung cancer: a review by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). <i>Clinical and Translational Oncology</i> , 2017, 19, 1183-1192.	1.2	7
7	Combining radiotherapy with immunotherapy: the past, the present and the future. <i>British Journal of Radiology</i> , 2017, 90, 20170157.	1.0	99
8	Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 415-429.	1.4	110
9	Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 735-746.	1.4	66
10	Immunomodulation by ionizing radiationâ€”impact for design of radioâ€”immunotherapies and for treatment of inflammatory diseases. <i>Immunological Reviews</i> , 2017, 280, 231-248.	2.8	140
11	Zymosan-a Protects the Hematopoietic System from Radiation-Induced Damage by Targeting TLR2 Signaling Pathway. <i>Cellular Physiology and Biochemistry</i> , 2017, 43, 457-464.	1.1	12
12	Mechanisms regulating T-cell infiltration and activity in solid tumors. <i>Annals of Oncology</i> , 2017, 28, xii18-xii32.	0.6	276
13	Neutrophils, a candidate biomarker and target for radiation therapy?. <i>Acta OncolÃ³gica</i> , 2017, 56, 1522-1530.	0.8	50
14	Down regulation of miR-143 promotes radiation â€” Induced thymic lymphoma by targeting B7H1. <i>Toxicology Letters</i> , 2017, 280, 116-124.	0.4	6
15	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 28-35.	0.9	18
16	Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 4866.	1.6	38
17	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. <i>Journal of Translational Medicine</i> , 2017, 15, 150.	1.8	26
18	Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future. <i>Frontiers in Oncology</i> , 2017, 7, 177.	1.3	59

#	ARTICLE	IF	CITATIONS
19	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. <i>Frontiers in Immunology</i> , 2017, 8, 267.	2.2	61
20	Expanding the therapeutic index of radiation therapy by normal tissue protection. <i>British Journal of Radiology</i> , 2019, 92, 20180008.	1.0	41
21	Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality?. <i>Npj Breast Cancer</i> , 2018, 4, 8.	2.3	38
22	The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy. <i>British Journal of Radiology</i> , 2018, 91, 20170762.	1.0	57
23	The mechanism for the radioprotective effects of zymosan in mice. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2413-2421.	1.6	11
24	Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer. <i>Cancer Letters</i> , 2018, 421, 59-62.	3.2	8
25	Pembrolizumab for the treatment of bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 107-114.	1.1	12
26	Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 104.	0.4	17
27	Immunotherapy in the Asiatic population: any differences from Caucasian population?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1482-S1493.	0.6	42
29	Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?. <i>Frontiers in Immunology</i> , 2018, 9, 2916.	2.2	6
30	Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. <i>Vaccines</i> , 2018, 6, 79.	2.1	7
31	Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment. <i>Cancers</i> , 2018, 10, 469.	1.7	36
32	Update Breast Cancer 2018 (Part 3) " Genomics, Individualized Medicine and Immune Therapies " in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1110-1118.	0.8	8
33	Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. <i>Frontiers in Oncology</i> , 2018, 8, 609.	1.3	17
34	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. <i>Cancer Treatment Reviews</i> , 2018, 70, 232-244.	3.4	36
35	Estimation of the risk for radiation-induced liver disease following photon- or proton-beam radiosurgery of liver metastases. <i>Radiation Oncology</i> , 2018, 13, 206.	1.2	7
36	Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. <i>Journal of Immunology Research</i> , 2018, 2018, 1-17.	0.9	147
37	Reactive Oxygen Species-Mediated Tumor Microenvironment Transformation: The Mechanism of Radioresistant Gastric Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-8.	1.9	55

#	ARTICLE	IF	CITATIONS
38	Comparison of microdosimetry-based absorbed doses to control tumours and clinically obtained tumour absorbed doses in treatments with ²²³ Ra. <i>Physics in Medicine and Biology</i> , 2018, 63, 145005.	1.6	4
39	Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. <i>Advanced Functional Materials</i> , 2018, 28, 1802540.	7.8	92
40	Priming the Abscopal Effect Using Multifunctional Smart Radiotherapy Biomaterials Loaded with Immunoadjuvants. <i>Frontiers in Oncology</i> , 2018, 8, 56.	1.3	34
41	Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 2-17.	0.8	24
42	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 104.	6.9	303
43	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. <i>Cancer Treatment Reviews</i> , 2019, 74, 49-60.	3.4	38
44	Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 2416-2429.	1.4	66
45	Radio-selective effects of a natural occurring muscle-derived dipeptide in A549 and normal cell lines. <i>Scientific Reports</i> , 2019, 9, 11513.	1.6	3
47	Immunotherapy in Ovarian Cancer: Are We There Yet?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2460-2471.	0.8	73
48	Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. <i>Oncogene</i> , 2019, 38, 6159-6171.	2.6	45
49	Treatment of a first patient with FLASH-radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 139, 18-22.	0.3	406
50	Colorectal cancer, radiotherapy and gut microbiota. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 212-222.	0.7	20
51	Rational combinations of immunotherapy with radiotherapy in ovarian cancer. <i>Lancet Oncology</i> , The, 2019, 20, e417-e433.	5.1	89
52	Tumor Microenvironment as A "Game Changer" in Cancer Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3212.	1.8	286
53	The CD73/Ado System "A New Player in RT Induced Adverse Late Effects". <i>Cancers</i> , 2019, 11, 1578.	1.7	16
54	Implementation of the Chick Chorioallantoic Membrane (CAM) Model in Radiation Biology and Experimental Radiation Oncology Research. <i>Cancers</i> , 2019, 11, 1499.	1.7	31
55	Bioactive Polysaccharide Nanoparticles Improve Radiation-Induced Abscopal Effect through Manipulation of Dendritic Cells. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 42661-42670.	4.0	33
56	A Model of Indirect Cell Death Caused by Tumor Vascular Damage after High-Dose Radiotherapy. <i>Cancer Research</i> , 2019, 79, 6044-6053.	0.4	10

#	ARTICLE	IF	CITATIONS
57	<p>Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6023-6032.	1.0	25
58	The potential combinational immunotherapiesfor treatment of hepatocellular carcinoma. <i>Journal of Interventional Medicine</i> , 2019, 2, 47-51.	0.2	3
59	Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects. <i>Radiation Oncology</i> , 2019, 14, 21.	1.2	67
60	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2019, 75, 707-711.	0.9	89
61	Current status of immune checkpoint inhibition in early-stage NSCLC. <i>Annals of Oncology</i> , 2019, 30, 1244-1253.	0.6	98
63	X-ray-activated nanosystems for theranostic applications. <i>Chemical Society Reviews</i> , 2019, 48, 3073-3101.	18.7	231
64	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 828-835.	0.4	46
65	Peripheral memory and naÃ~ve T cells in non-small cell lung cancer patients with lung metastases undergoing stereotactic body radiotherapy: predictors of early tumor response. <i>Cancer Cell International</i> , 2019, 19, 121.	1.8	17
66	Immunotherapy and the Interventional Oncologist: Challenges and Opportunitiesâ€™A Society of Interventional Oncology White Paper. <i>Radiology</i> , 2019, 292, 25-34.	3.6	57
67	Cascadeâ€™amplification of therapeutic efficacy: An emerging opportunity in cancer treatment. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2019, 11, e1555.	3.3	4
68	Biological Benefits of Ultra-high Dose Rate FLASH Radiotherapy: Sleeping Beauty Awoken. <i>Clinical Oncology</i> , 2019, 31, 407-415.	0.6	324
69	Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With <i>CD274/PD-L1</i> Amplification. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	10
70	Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 698.	2.2	64
71	The Role of Radiation Oncology in Immuno-Oncology. <i>Oncologist</i> , 2019, 24, S42-S52.	1.9	23
72	Chemoradiotherapy-Induced CD4+ and CD8+ T-Cell Alterations to Predict Patient Outcomes in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 73.	1.3	17
73	Radiotherapy for Melanoma: More than DNA Damage. <i>Dermatology Research and Practice</i> , 2019, 2019, 1-9.	0.3	18
74	Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 120.	1.8	22
75	Reactive Oxygen Species (ROS)-Based Nanomedicine. <i>Chemical Reviews</i> , 2019, 119, 4881-4985.	23.0	1,519

#	ARTICLE	IF	CITATIONS
76	Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. <i>Frontiers of Medicine</i> , 2019, 13, 12-23.	1.5	14
77	Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 199-206.	1.0	19
78	Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 87.	3.5	213
79	Abscopal effect of high-dose-rate brachytherapy on pelvic bone metastases from renal cell carcinoma: a case report. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 458-461.	0.4	8
80	Lymphopenia Is Associated with Gross Target Volumes and Fractions in Hepatocellular Carcinoma Patients Treated with External Beam Radiation Therapy and Also Indicates Worse Overall Survival. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-12.	0.8	9
81	Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 24.	1.8	100
82	Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?. <i>Frontiers in Immunology</i> , 2018, 9, 3107.	2.2	76
83	50-Cy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 320-334.	0.4	28
84	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	0.6	60
85	Intracellular RNA Sensing in Mammalian Cells: Role in Stress Response and Cancer Therapies. <i>International Review of Cell and Molecular Biology</i> , 2019, 344, 31-89.	1.6	30
86	Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2019, 16, 401-409.	4.8	105
87	Harnessing radiation to improve immunotherapy: better with particles?. <i>British Journal of Radiology</i> , 2020, 93, 20190224.	1.0	53
88	Developments in anticancer vaccination: budding new adjuvants. <i>Biological Chemistry</i> , 2020, 401, 435-446.	1.2	2
89	Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes. <i>Frontiers in Oncology</i> , 2020, 9, 1381.	1.3	17
90	Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. <i>European Journal of Cancer</i> , 2020, 124, 67-76.	1.3	16
91	Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial. <i>British Journal of Cancer</i> , 2020, 123, 1616-1624.	2.9	17
92	Evaluation of the prognostic value of derived neutrophil/lymphocyte ratio in early stage non-small cell lung cancer patients treated with stereotactic ablative radiotherapy. <i>Medicine (United States)</i> , 2020, 99, e22603.	0.4	3
93	Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. <i>Frontiers in Immunology</i> , 2020, 11, 577869.	2.2	147

#	ARTICLE	IF	CITATIONS
94	Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 2762.	1.7	41
95	High versus low dose irradiation for tumor immune reprogramming. <i>Current Opinion in Biotechnology</i> , 2020, 65, 268-283.	3.3	13
96	Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. <i>Human Gene Therapy</i> , 2020, 31, 1132-1139.	1.4	24
97	<p>HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6859-6871.	1.0	23
98	GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/ unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2008-2015.	1.3	10
99	Advances in Radiobiology of Stereotactic Ablative Radiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1165.	1.3	34
100	Brachytherapy in a Single Dose of 10Gy as an â€œin situâ€•Vaccination. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4585.	1.8	8
101	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , 2020, 14, 1589-1615.	2.1	33
102	Avelumabâ€™cetuximabâ€™radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). <i>European Journal of Cancer</i> , 2020, 141, 21-29.	1.3	48
103	Carbon Ion Radiobiology. <i>Cancers</i> , 2020, 12, 3022.	1.7	104
104	Preparedness of the cancer hospitals and changes in oncosurgical practices during COVIDâ€™19 pandemic in India: A crossâ€™sectional study. <i>Journal of Surgical Oncology</i> , 2020, 122, 1276-1287.	0.8	8
105	Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 1625.	1.3	12
106	Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. <i>Lancet Oncology</i> , The, 2020, 21, e419-e430.	5.1	128
107	Palladium(II)â€™ ³ â€™Allyl Complexes Bearing <i>N</i>â€™Trifluoromethyl <i>N</i>â€™Heterocyclic Carbenes: A New Generation of Anticancer Agents that Restrain the Growth of Highâ€™Grade Serous Ovarian Cancer Tumoroids. <i>Chemistry - A European Journal</i> , 2020, 26, 11868-11876.	1.7	62
108	Nanomaterials for Combinational Radioâ€™Immuno Oncotherapy. <i>Advanced Functional Materials</i> , 2020, 30, 1910676.	7.8	45
109	Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 212-224.	0.4	72
110	Immune Therapy Opportunities in Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e228-e240.	1.8	25
111	Irradiated tumor cellâ€™derived microparticles mediate tumor eradication via cell killing and immune reprogramming. <i>Science Advances</i> , 2020, 6, eaay9789.	4.7	139

#	ARTICLE	IF	CITATIONS
112	<p></p>Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance</p></p>. OncoTargets and Therapy, 2020, Volume 13, 6037-6050.	1.0	23
113	Radiation-induced bystander and abscopal effects: important lessons from preclinical models. British Journal of Cancer, 2020, 123, 339-348.	2.9	71
114	Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. , 2020, 8, e000289.		51
115	Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. International Journal of Radiation Oncology Biology Physics, 2020, 108, 196-203.	0.4	77
116	Manganese Oxide Nanomaterials: Synthesis, Properties, and Theranostic Applications. Advanced Materials, 2020, 32, e1905823.	11.1	346
117	The Emerging Role of Local Therapy in Metastatic Prostate Cancer. Current Oncology Reports, 2020, 22, 2.	1.8	7
118	<p></p>Predictive Value of Lymphocyte-Related Blood Parameters at the Time Point of Lymphocyte Nadir During Radiotherapy in Breast Cancer</p></p>. OncoTargets and Therapy, 2020, Volume 13, 151-161.	1.0	7
119	From Theranostics to Immunotheranostics: the Concept. Nuclear Medicine and Molecular Imaging, 2020, 54, 81-85.	0.6	3
120	Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study. ERJ Open Research, 2020, 6, 00165-2019.	1.1	24
121	Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management. Pharmaceuticals, 2020, 13, 76.	1.7	25
122	SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1 Resistant Model of Non-Small Cell Lung Cancer. Cancer Immunology Research, 2020, 8, 883-894.	1.6	48
123	Combination therapy: Future directions of immunotherapy in small cell lung cancer. Translational Oncology, 2021, 14, 100889.	1.7	35
124	Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC. Cancer Medicine, 2021, 10, 3-14.	1.3	28
125	Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy. Journal of Controlled Release, 2021, 330, 1080-1094.	4.8	32
126	Radiation-induced abscopal reproductive effect is driven by TNF- α /p38 MAPK/Rac1 axis in Sertoli cells. Theranostics, 2021, 11, 5742-5758.	4.6	10
127	Radioimmunotherapy: future prospects from the perspective of brachytherapy. Journal of Contemporary Brachytherapy, 2021, 13, 458-467.	0.4	6
128	Radiotherapy for Hepatocellular Carcinoma. , 2021, , 189-200.		0
129	Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment. Human Vaccines and Immunotherapeutics, 2021, 17, 1555-1567.	1.4	17

#	ARTICLE	IF	CITATIONS
130	Cisplatin nanoparticles boost abscopal effect of radiation plus anti-PD1 therapy. <i>Biomaterials Science</i> , 2021, 9, 3019-3027.	2.6	16
131	Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields. <i>Journal of Cancer</i> , 2021, 12, 1094-1104.	1.2	12
132	Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 594-602.	0.4	48
133	Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 537-547.	1.0	9
134	ICAM-1 orchestrates the abscopal effect of tumor radiotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	22
135	The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?. <i>Biomarker Research</i> , 2021, 9, 22.	2.8	13
136	Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 85-88.	0.9	8
137	Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. <i>Cancer Biology and Therapy</i> , 2021, 22, 175-183.	1.5	13
138	Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect. <i>Journal of Controlled Release</i> , 2021, 331, 480-490.	4.8	66
140	Radiotherapy in the Era of Immunotherapy—With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?. <i>Frontiers in Oncology</i> , 2021, 11, 662236.	1.3	19
141	Ferroptosis, radiotherapy, and combination therapeutic strategies. <i>Protein and Cell</i> , 2021, 12, 836-857.	4.8	167
142	Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 138.	4.2	20
143	Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy. <i>BJR case Reports</i> , 2021, 7, 20200170.	0.1	1
144	The Efficacy and Safety of Hypofractionated Radiation Therapy With Tomotherapy for Advanced or Recurrent Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 559112.	1.3	4
145	Turning tumors from cold to inflamed to improve immunotherapy response. <i>Cancer Treatment Reviews</i> , 2021, 101, 102227.	3.4	42
146	Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients. , 2021, 9, e002512.		8
147	Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 2837-2860.	1.1	4
148	Interfering with Tumor Hypoxia for Radiotherapy Optimization. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 197.	3.5	70

#	ARTICLE	IF	CITATIONS
149	Is There a Benefit of Combining Immunotherapy and Radiotherapy in Bladder Cancer?. <i>Clinical Oncology</i> , 2021, 33, 407-414.	0.6	6
150	Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy. <i>Medicine (United States)</i> , 2021, 100, e26674.	0.4	4
151	Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. , 2021, 9, e002256.		18
152	Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3420-3431.	1.3	5
153	Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 685126.	2.2	5
154	The Abscopal Effect in the Era of Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7204.	1.8	22
155	Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 737425.	1.3	6
156	Evaluation of indirect damage and damage saturation effects in doseâ€“response curves of hypofractionated radiotherapy of early-stage NSCLC and brain metastases. <i>Radiotherapy and Oncology</i> , 2021, 161, 1-8.	0.3	4
157	Multimomics Differences in Lung Squamous Cell Carcinoma Patients with High Radiosensitivity Index Compared with Those with Low Radiosensitivity Index. <i>Disease Markers</i> , 2021, 2021, 1-11.	0.6	6
158	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , 2021, 9, 1075.	1.4	46
159	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. <i>Cancer Discovery</i> , 2022, 12, 108-133.	7.7	165
160	Combining the past and present to advance immuno-radiotherapy of cancer. <i>International Reviews of Immunology</i> , 2023, 42, 26-42.	1.5	8
161	Sintilimab, stereotactic body radiotherapy and granulocyteâ€“macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. <i>Radiation Oncology</i> , 2021, 16, 177.	1.2	14
162	A Radioresponse-Related lncRNA Biomarker Signature for Risk Classification and Prognosis Prediction in Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-16.	0.6	15
163	Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. <i>Practical Radiation Oncology</i> , 2022, 12, e34-e39.	1.1	3
164	PI3KÎ³ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model. <i>European Journal of Cancer</i> , 2021, 157, 450-463.	1.3	13
165	Macrophage contributes to radiation-induced anti-tumor abscopal effect on transplanted breast cancer by HMGB1/TNF-Î± signaling factors. <i>International Journal of Biological Sciences</i> , 2021, 17, 926-941.	2.6	17
166	Commensal microbiota in the digestive tract: a review of its roles in carcinogenesis and radiotherapy. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	2

#	ARTICLE	IF	CITATIONS
167	Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma. <i>Frontiers in Immunology</i> , 2020, 11, 594212.	2.2	12
168	Microdosimetry-based determination of tumour control probability curves for treatments with ²²⁵ Ac-PSMA of metastatic castration resistant prostate cancer. <i>Physics in Medicine and Biology</i> , 2020, 65, 235012.	1.6	7
170	Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy. <i>Oncotarget</i> , 2017, 8, 43427-43438.	0.8	31
171	The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. <i>Cancer Biology and Medicine</i> , 2020, 17, 599-611.	1.4	45
172	Current and future immunotherapy approaches in ovarian cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1714-1714.	0.7	19
173	Lymphopenia association with accelerated hyperfractionation and its effects on limited-stage small cell lung cancer patientsâ€™ clinical outcomes. <i>Annals of Translational Medicine</i> , 2019, 7, 385-385.	0.7	11
174	Harnessing Tumor Immune Ecosystem Dynamics to Personalize Radiation Therapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
175	Identification of Aberrantly Expressed Genes in Murine Glioblastoma During Radiotherapy via Bioinformatic Data Mining. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3839-3851.	1.0	3
176	Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. <i>Current Medicinal Chemistry</i> , 2020, 26, 7196-7211.	1.2	9
177	Targeting DNA Double-Strand Break (DSB) Repair to Counteract Tumor Radio-resistance. <i>Current Drug Targets</i> , 2019, 20, 891-902.	1.0	15
178	The future of radiation-induced abscopal response: beyond conventional radiotherapy approaches. <i>Future Oncology</i> , 2020, 16, 1137-1151.	1.1	22
179	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. <i>Ecanermedalscience</i> , 2020, 14, 1036.	0.6	5
180	Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response. <i>Cancers</i> , 2020, 12, 2835.	1.7	8
181	Apatinib Combined with Local Irradiation Leads to Systemic Tumor Control via Reversal of Immunosuppressive Tumor Microenvironment in Lung Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 406-418.	1.3	6
182	All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. <i>Science Immunology</i> , 2021, 6, .	5.6	24
183	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 743582.	1.6	14
184	True abscopal effect in a patient with metastatic non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 194.	1.2	8
185	ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. <i>Science Advances</i> , 2021, 7, eabf6290.	4.7	79

#	ARTICLE	IF	CITATIONS
186	Abscopal effect in the radio and immunotherapy. <i>Radiation Oncology Journal</i> , 2021, 39, 247-253.	0.7	15
187	Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. <i>Neoplasia</i> , 2021, 23, 1110-1122.	2.3	15
188	Radio-Immunotherapy: A Case Report of "Abscopal Hyper-Progression"? <i>Cureus</i> , 2020, 12, e10117.	0.2	2
189	IMMUNOTERAPÄ° VE RADYOTERAPÄ° KOMBÄ°NASYONU. <i>UludaÄŸ Āœniversitesi TÄ±p FakÄ¼ltesi Dergisi</i> , 0, , .	0.2	1
190	Characteristics of stereotactic radiotherapy clinical trials registered on ClinicalTrials.gov. <i>Translational Cancer Research</i> , 2021, 10, 4316-4326.	0.4	0
191	Unveiling the active sites on ferrihydrite with apparent catalase-like activity for potentiating radiotherapy. <i>Nano Today</i> , 2021, 41, 101317.	6.2	102
192	Peptide hydrogels loaded with irradiated tumor cell secretions enhance cancer immunotherapy. <i>Nano Today</i> , 2021, 41, 101323.	6.2	16
193	Immunotherapy and Radiation. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 205-213.	0.8	2
195	Summary of the lecture given on June 1, 2017 on the occasion of the Jacob I. Fabrikant Award ceremony. <i>Journal of Radiosurgery and SBRT</i> , 2017, 5, 1-3.	0.2	0
196	Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor. <i>American Journal of Cancer Research</i> , 2018, 8, 1689-1696.	1.4	11
197	Abscopal effect of local irradiation treatment for thymoma: a case report. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 2234-2240.	0.0	2
199	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. <i>Cancers</i> , 2021, 13, 5819.	1.7	4
200	Hollow Mesoporous Manganese Oxides: Application in Cancer Diagnosis and Therapy. <i>Small</i> , 2022, 18, e2106511.	5.2	29
201	First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations. <i>Frontiers in Oncology</i> , 2022, 12, 766066.	1.3	3
202	Lighting up the tumor fire with low-dose irradiation. <i>Trends in Immunology</i> , 2022, 43, 173-179.	2.9	26
203	The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2022, 168, 28-36.	0.3	17
204	Transformable Galliumâ€Based Liquid Metal Nanoparticles for Tumor Radiotherapy Sensitization. <i>Advanced Healthcare Materials</i> , 2022, 11, e2102584.	3.9	19
205	Transcriptome Profiling Reveals Novel Radiosensitivity Predictors by Integrating Molecular Subtype and Radiosensitivity Signature in Triple-Negative Breast Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
206	Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 1162.	1.7	9
207	Radiotherapy assisted with biomaterials to trigger antitumor immunity. <i>Chinese Chemical Letters</i> , 2022, 33, 4169-4174.	4.8	17
208	The combination of radiotherapy and immunotherapy is effective and well tolerated for unresectable biliary tract cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	2
209	The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 635-647.	0.4	11
210	Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020. <i>JAMA Network Open</i> , 2022, 5, e220173.	2.8	3
211	Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy. <i>BMC Pulmonary Medicine</i> , 2022, 22, 75.	0.8	7
212	Cervical cancer " times" they are a changing: A report from the Society of Gynecologic Oncology journal club. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100949.	0.3	0
213	Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-8.	0.9	3
214	Radiotherapy: Brightness and darkness in the era of immunotherapy. <i>Translational Oncology</i> , 2022, 19, 101366.	1.7	17
215	Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade. <i>Advances in Radiation Oncology</i> , 2022, 7, 100931.	0.6	4
216	Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor. <i>Cancer Management and Research</i> , 2021, Volume 13, 9247-9259.	0.9	3
217	Progress in Radiotherapy for Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 868034.	1.3	18
220	Development and validation of an immune-related gene signature for predicting the radiosensitivity of lower-grade gliomas. <i>Scientific Reports</i> , 2022, 12, 6698.	1.6	6
222	Integration of immune and hypoxia gene signatures improves the prediction of radiosensitivity in breast cancer.. <i>American Journal of Cancer Research</i> , 2022, 12, 1222-1240.	1.4	0
223	A Biomathematical Model of Tumor Response to Radioimmunotherapy With $\hat{\pm}$ PDL1 and $\hat{\pm}$ CTLA4. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2023, 20, 808-821.	1.9	3
224	Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
225	Development of a prediction model for radiotherapy response among patients with head and neck squamous cell carcinoma based on the tumor immune microenvironment and hypoxia signature. <i>Cancer Medicine</i> , 2022, 11, 4673-4687.	1.3	7
226	Size-changeable nanoprobe for the combined radiotherapy and photodynamic therapy of tumor. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2655-2667.	3.3	13

#	ARTICLE	IF	CITATIONS
227	Radiomics-guided radiation therapy: opportunities and challenges. <i>Physics in Medicine and Biology</i> , 2022, 67, 12TR02.	1.6	8
228	LncRNAs as Theragnostic Biomarkers for Predicting Radioresistance in Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
229	Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy. <i>Cancer Letters</i> , 2022, 541, 215719.	3.2	17
230	Bidirectional effects of intestinal microbiota and antibiotics: a new strategy for colorectal cancer treatment and prevention. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2387-2404.	1.2	6
231	Insight of a Metabolic Prognostic Model to Identify Tumor Environment and Drug Vulnerability for Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
232	FLASH radiotherapy: an emerging approach in radiation therapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 343-351.	0.3	13
233	Integrated Mn (III)-Doped Nanosystem for Optimizing Photothermal Ablation: Amplifying Hyperthermia-Induced STING Pathway and Enhancing Antitumor Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
234	Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study. <i>Radiation Oncology</i> , 2022, 17, .	1.2	5
235	Low-dose irradiation for reversing immunotherapy resistance: how to translate?. , 2022, 10, e004939.		8
236	Ionizing Radiation-Induced Tumor Cell-Derived Microparticles Prevent Lung Metastasis by Remodeling the Pulmonary Immune Microenvironment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 502-515.	0.4	8
237	Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
238	PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
239	Recent progresses on radiotherapeutics-based treatment of cancer with two-dimensional nanomaterials. <i>Applied Materials Today</i> , 2022, 29, 101584.	2.3	1
240	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	142
241	Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications. <i>Anticancer Research</i> , 2022, 42, 3767-3778.	0.5	4
242	Immunotherapy Recall: Chemoradiation-Induced Reactivation of Immune Checkpoint Inhibitor Nephritis. <i>JCO Precision Oncology</i> , 2022, , .	1.5	0
243	Impressive Results after "Metabolism-Guided" Lattice Irradiation in Patients Submitted to Palliative Radiation Therapy: Preliminary Results of LATTICE_01 Multicenter Study. <i>Cancers</i> , 2022, 14, 3909.	1.7	10
244	Deciphering the Biological Effects of Radiotherapy in Cancer Cells. <i>Biomolecules</i> , 2022, 12, 1167.	1.8	9

#	ARTICLE	IF	CITATIONS
245	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	1
246	Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial. <i>Hepatology International</i> , 2022, 16, 1179-1187.	1.9	6
247	Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
248	Mechanisms of Action of Radiotherapy and Immunotherapy in Lung Cancer: Implications for Clinical Practice. <i>Medical Radiology</i> , 2022, , .	0.0	1
249	PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
250	Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
251	Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling. <i>Gut Microbes</i> , 2022, 14, .	4.3	20
252	Is anti-PD-1 immunotherapy a means for post-irradiation tumor clearance in head and neck cancer?., 2022, 39, .		0
253	Targeting Tumor Physical Microenvironment for Improved Radiotherapy. <i>Small Methods</i> , 2022, 6, .	4.6	5
254	ROS-Based Cancer Radiotherapy. <i>Nanomedicine and Nanotoxicology</i> , 2022, , 265-309.	0.1	1
255	First communication on the efficacy of combined ¹⁷⁷ Lutetium-PSMA with immunotherapy outside prostate cancer. , 2022, 10, e005383.		3
256	Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. <i>Annals of Oncology</i> , 2023, 34, 101-110.	0.6	39
257	An Overview of Recent Advancements on Manganese-Based Nanostructures and Their Application for ROS-Mediated Tumor Therapy. , 2022, 4, 2415-2433.		2
258	Integrated manganese (III)-doped nanosystem for optimizing photothermal ablation: Amplifying hyperthermia-induced STING pathway and enhancing antitumor immunity. <i>Acta Biomaterialia</i> , 2023, 155, 601-617.	4.1	8
259	Mechanism of exosomes in the tumor microenvironment in the abscopal effect (Review). <i>International Journal of Oncology</i> , 2022, 62, .	1.4	1
260	Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
261	Lactic acid modified rare earth-based nanomaterials for enhanced radiation therapy by disturbing the glycolysis. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	1
262	Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. <i>Chemical Society Reviews</i> , 2023, 52, 47-96.	18.7	19

#	ARTICLE	IF	CITATIONS
263	Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC. <i>International Journal of Oncology</i> , 2022, 62, .	1.4	2
264	Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastroesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group). <i>BMC Cancer</i> , 2022, 22, .	1.1	2
265	The Lymphatic Endothelium in the Context of Radioimmuno-Oncology. <i>Cancers</i> , 2023, 15, 21.	1.7	0
266	Ovarian Cancer Radiosensitivity: What Have We Understood So Far?. <i>Life</i> , 2023, 13, 6.	1.1	0
267	Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
268	GPC2 antibody drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies. , 2022, 10, e004704.		2
269	Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
270	Are PD-1 inhibitors effective for recurrent/metastatic nasopharyngeal carcinoma? Meta-analysis and systematic review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
271	Challenges and exploration for immunotherapies targeting cold colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 55-68.	0.8	3
272	Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series. <i>Translational Andrology and Urology</i> , 2023, 12, 128-138.	0.6	3
273	Biodegradable nanomaterials for diagnosis and therapy of tumors. <i>Journal of Materials Chemistry B</i> , 2023, 11, 1829-1848.	2.9	9
274	Radiation therapy in the era of immune treatment for hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
275	Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2023, 11, 486-500.	1.6	7
276	Influence of neo-adjuvant radiotherapy on the intestinal microbiota of rectal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6085-6096.	1.2	0
277	æjĕă...%ăŠĕĖÿèˆăæÿè,ıç~æ²»ç—ç”ç©ŕçŽ°çŠŕă,Žă±•æœ. <i>Chinese Science Bulletin</i> , 2023, , .	0.4	1
278	Immune Checkpoint Inhibition and Radiotherapy in Head and Neck Squamous Cell Carcinoma: Synergisms and Resistance Mechanisms. , 2023, , 11-21.		0
279	Transforming Cold Tumors into Hot Ones with a Metal-Organic Framework-Based Biomimetic Nanosystem for Enhanced Immunotherapy. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 17470-17484.	4.0	6
280	FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients. <i>Cancer Letters</i> , 2023, 562, 216145.	3.2	1

#	ARTICLE	IF	CITATIONS
281	DNA Nanoclusters Combined with Oneâ€Shot Radiotherapy Augment Cancer Immunotherapy Efficiency. <i>Advanced Materials</i> , 2023, 35, .	11.1	6
282	Hafnium oxide nanoparticles coated ATR inhibitor to enhance the radiotherapy and potentiate antitumor immune response. <i>Chemical Engineering Journal</i> , 2023, 461, 142085.	6.6	4
285	Effect of triple therapy with low-dose total body irradiation and hypo-fractionated radiation plus anti-programmed cell death protein 1 blockade on abscopal antitumor immune responses in breast cancer. <i>International Immunopharmacology</i> , 2023, 117, 110026.	1.7	1
286	Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	3
287	Molecular imaging for cancer immunotherapy. , 2023, 1, 3-17.		4
288	Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Current Medical Science</i> , 0, , .	0.7	0
289	Anti-PD-1 immunotherapy with dose-adjusted ultra-hypofractionated re-irradiation in patients with locoregionally recurrent head and neck cancer. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	3
290	Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
291	Opportunities and challenges of low-dose radiation to enable immunotherapy efficacy. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	0
299	Chemotherapy-induced metastasis: molecular mechanisms and clinical therapies. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 1725-1736.	2.8	4
305	Drug testing. , 2023, , 45-48.		0
311	Procedural technique development in radiation oncology. , 2023, , 77-80.		0